These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 32814708)

  • 1. Curative in vivo hematopoietic stem cell gene therapy of murine thalassemia using large regulatory elements.
    Wang H; Georgakopoulou A; Li C; Liu Z; Gil S; Bashyam A; Yannaki E; Anagnostopoulos A; Pande A; Izsvák Z; Papayannopoulou T; Lieber A
    JCI Insight; 2020 Aug; 5(16):. PubMed ID: 32814708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo hematopoietic stem cell gene therapy ameliorates murine thalassemia intermedia.
    Wang H; Georgakopoulou A; Psatha N; Li C; Capsali C; Samal HB; Anagnostopoulos A; Ehrhardt A; Izsvák Z; Papayannopoulou T; Yannaki E; Lieber A
    J Clin Invest; 2019 Feb; 129(2):598-615. PubMed ID: 30422819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reactivation of γ-globin in adult β-YAC mice after ex vivo and in vivo hematopoietic stem cell genome editing.
    Li C; Psatha N; Sova P; Gil S; Wang H; Kim J; Kulkarni C; Valensisi C; Hawkins RD; Stamatoyannopoulos G; Lieber A
    Blood; 2018 Jun; 131(26):2915-2928. PubMed ID: 29789357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Vivo HSC Gene Therapy Using a Bi-modular HDAd5/35++ Vector Cures Sickle Cell Disease in a Mouse Model.
    Li C; Wang H; Georgakopoulou A; Gil S; Yannaki E; Lieber A
    Mol Ther; 2021 Feb; 29(2):822-837. PubMed ID: 32949495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted Integration and High-Level Transgene Expression in AAVS1 Transgenic Mice after In Vivo HSC Transduction with HDAd5/35++ Vectors.
    Li C; Mishra AS; Gil S; Wang M; Georgakopoulou A; Papayannopoulou T; Hawkins RD; Lieber A
    Mol Ther; 2019 Dec; 27(12):2195-2212. PubMed ID: 31494053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amelioration of murine beta-thalassemia through drug selection of hematopoietic stem cells transduced with a lentiviral vector encoding both gamma-globin and the MGMT drug-resistance gene.
    Zhao H; Pestina TI; Nasimuzzaman M; Mehta P; Hargrove PW; Persons DA
    Blood; 2009 Jun; 113(23):5747-56. PubMed ID: 19365082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo transduction of primitive mobilized hematopoietic stem cells after intravenous injection of integrating adenovirus vectors.
    Richter M; Saydaminova K; Yumul R; Krishnan R; Liu J; Nagy EE; Singh M; Izsvák Z; Cattaneo R; Uckert W; Palmer D; Ng P; Haworth KG; Kiem HP; Ehrhardt A; Papayannopoulou T; Lieber A
    Blood; 2016 Nov; 128(18):2206-2217. PubMed ID: 27554082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analysis of FV vectors with human α- or β-globin gene regulatory elements for the correction of β-thalassemia.
    Morianos I; Siapati EK; Pongas G; Vassilopoulos G
    Gene Ther; 2012 Mar; 19(3):303-11. PubMed ID: 21734726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene Therapy for beta-thalassemia.
    Malik P; Arumugam PI
    Hematology Am Soc Hematol Educ Program; 2005; ():45-50. PubMed ID: 16304358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic base editing of human hematopoietic stem cells.
    Zeng J; Wu Y; Ren C; Bonanno J; Shen AH; Shea D; Gehrke JM; Clement K; Luk K; Yao Q; Kim R; Wolfe SA; Manis JP; Pinello L; Joung JK; Bauer DE
    Nat Med; 2020 Apr; 26(4):535-541. PubMed ID: 32284612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The new self-inactivating lentiviral vector for thalassemia gene therapy combining two HPFH activating elements corrects human thalassemic hematopoietic stem cells.
    Papanikolaou E; Georgomanoli M; Stamateris E; Panetsos F; Karagiorga M; Tsaftaridis P; Graphakos S; Anagnou NP
    Hum Gene Ther; 2012 Jan; 23(1):15-31. PubMed ID: 21875313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lentiviral Transfer of γ-Globin with Fusion Gene NUP98-HOXA10HD Expands Hematopoietic Stem Cells and Ameliorates Murine β-Thalassemia.
    Zhao HF; Abraham A; Kim YS; Wang YD; Pestina T; Zhan J; Humphries K; Nienhuis AW; Persons DA
    Mol Ther; 2017 Mar; 25(3):593-605. PubMed ID: 28190779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safe mobilization of CD34+ cells in adults with β-thalassemia and validation of effective globin gene transfer for clinical investigation.
    Boulad F; Wang X; Qu J; Taylor C; Ferro L; Karponi G; Bartido S; Giardina P; Heller G; Prockop SE; Maggio A; Sadelain M; Rivière I
    Blood; 2014 Mar; 123(10):1483-6. PubMed ID: 24429337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reactivation of γ-globin expression using a minicircle DNA system to treat β-thalassemia.
    Ma SP; Gao XX; Zhou GQ; Zhang HK; Yang JM; Wang WJ; Song XM; Chen HY; Lu DR
    Gene; 2022 Apr; 820():146289. PubMed ID: 35143940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo HSPC gene therapy with base editors allows for efficient reactivation of fetal γ-globin in β-YAC mice.
    Li C; Georgakopoulou A; Mishra A; Gil S; Hawkins RD; Yannaki E; Lieber A
    Blood Adv; 2021 Feb; 5(4):1122-1135. PubMed ID: 33620431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentially therapeutic levels of anti-sickling globin gene expression following lentivirus-mediated gene transfer in sickle cell disease bone marrow CD34+ cells.
    Urbinati F; Hargrove PW; Geiger S; Romero Z; Wherley J; Kaufman ML; Hollis RP; Chambers CB; Persons DA; Kohn DB; Wilber A
    Exp Hematol; 2015 May; 43(5):346-351. PubMed ID: 25681747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene Therapy for Sickle Cell Disease: A Lentiviral Vector Comparison Study.
    Urbinati F; Campo Fernandez B; Masiuk KE; Poletti V; Hollis RP; Koziol C; Kaufman ML; Brown D; Mavilio F; Kohn DB
    Hum Gene Ther; 2018 Oct; 29(10):1153-1166. PubMed ID: 30198339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correction of murine sickle cell disease using gamma-globin lentiviral vectors to mediate high-level expression of fetal hemoglobin.
    Pestina TI; Hargrove PW; Jay D; Gray JT; Boyd KM; Persons DA
    Mol Ther; 2009 Feb; 17(2):245-52. PubMed ID: 19050697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plerixafor+G-CSF-mobilized CD34+ cells represent an optimal graft source for thalassemia gene therapy.
    Karponi G; Psatha N; Lederer CW; Adair JE; Zervou F; Zogas N; Kleanthous M; Tsatalas C; Anagnostopoulos A; Sadelain M; Rivière I; Stamatoyannopoulos G; Yannaki E
    Blood; 2015 Jul; 126(5):616-9. PubMed ID: 26089395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A New Era for Hemoglobinopathies: More Than One Curative Option.
    Psatha N; Papayanni PG; Yannaki E
    Curr Gene Ther; 2017; 17(5):364-378. PubMed ID: 29357790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.